Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Inspire Medical Systems ( (INSP) ) just unveiled an announcement.
Inspire Medical Systems reported first‑quarter 2026 results on May 4, 2026, showing revenue up 1.6% year over year to $204.6 million and gross margin improving to 86.5%, driven by a higher mix of its Inspire V system. The company posted a net loss of $11.3 million, or diluted EPS of $(0.39), but generated adjusted net earnings of $2.8 million, adjusted diluted EPS of $0.10, and $12.8 million in operating cash flow, while operating expenses rose modestly on higher marketing, legal and employee costs.
Management highlighted that growth was dampened by coding and reimbursement disruptions, including the phase‑out of a key CPT code and the impact of the WISeR program, which complicated Medicare reimbursement for Inspire V cases. Reflecting these headwinds, Inspire cut its 2026 revenue outlook to $825 million–$875 million, implying a 4%–10% decline versus 2025, but guided to a positive adjusted operating margin of 2%–4% and signaled expectations for a return to revenue growth in 2027 as reimbursement issues are resolved and clinical outcomes support broader adoption of Inspire V.
The most recent analyst rating on (INSP) stock is a Hold with a $64.00 price target. To see the full list of analyst forecasts on Inspire Medical Systems stock, see the INSP Stock Forecast page.
Spark’s Take on INSP Stock
According to Spark, TipRanks’ AI Analyst, INSP is a Neutral.
The score is supported by strong financial performance (profitability inflection, high gross margins, and a conservative balance sheet) and a reasonable earnings multiple, but is pulled down by very weak technicals (sharp downtrend, oversold conditions) and elevated 2026 execution risk from reimbursement/coding uncertainty and near-term disruption highlighted on the earnings call.
To see Spark’s full report on INSP stock, click here.
More about Inspire Medical Systems
Inspire Medical Systems, Inc. is a medical technology company focused on developing and commercializing innovative, minimally invasive neurostimulation solutions for patients with moderate to severe obstructive sleep apnea. Its proprietary Inspire therapy is the first FDA, EU MDR and PDMA‑approved neurostimulation technology for this indication, positioning the company in a specialized segment of the sleep apnea treatment market.
Average Trading Volume: 1,139,172
Technical Sentiment Signal: Sell
Current Market Cap: $1.63B
Find detailed analytics on INSP stock on TipRanks’ Stock Analysis page.